Cargando…
Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing
IMPORTANCE: Transmucosal immediate-release fentanyl (TIRF) drugs are potent, rapid-acting opioids approved to treat breakthrough pain in patients with cancer who are tolerant to other around-the-clock opioid analgesics. In March 2012, a US Food and Drug Administration–approved Risk Evaluation and Mi...
Autores principales: | Fleischman, William, Auth, Doris, Shah, Nilay D., Agrawal, Shantanu, Ross, Joseph S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450314/ https://www.ncbi.nlm.nih.gov/pubmed/30924899 http://dx.doi.org/10.1001/jamanetworkopen.2019.1340 |
Ejemplares similares
-
Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products
por: Pergolizzi, Joseph V, et al.
Publicado: (2013) -
Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain
por: Prommer, Eric, et al.
Publicado: (2012) -
Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology
por: Mystakidou, Kyriaki, et al.
Publicado: (2007) -
Efficacy of Oral Transmucosal Fentanyl Citrate for Premedication in Patients for Surgery under General Anesthesia
por: Singh, Raj Bahadur, et al.
Publicado: (2017) -
Oral transmucosal fentanyl citrate analgesia in prehospital trauma care: an observational cohort study
por: Pietsch, Urs, et al.
Publicado: (2023)